104 related articles for article (PubMed ID: 29413509)
1. Evaluation of the clinical characteristics of everolimus-induced lung injury and determination of associated risk factors.
Abe M; Tsushima K; Ikari J; Kawata N; Terada J; Tanabe N; Tatsumi K
Respir Med; 2018 Jan; 134():6-11. PubMed ID: 29413509
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis.
Saito Y; Terasaki Y; Kashiwada T; Tanaka T; Takei H; Kimura G; Kondo Y; Kawagoe T; Matsushita A; Noro R; Minegishi Y; Kamio K; Seike M; Gemma A
J Nippon Med Sch; 2024 May; 91(2):207-217. PubMed ID: 38233124
[TBL] [Abstract][Full Text] [Related]
3. Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma.
Mizuno R; Asano K; Mikami S; Nagata H; Kaneko G; Oya M
Jpn J Clin Oncol; 2012 May; 42(5):442-6. PubMed ID: 22438405
[TBL] [Abstract][Full Text] [Related]
4. Prognostic roles of KL-6 in disease severity and lung injury in COVID-19 patients: A longitudinal retrospective analysis.
Deng K; Fan Q; Yang Y; Deng X; He R; Tan Y; Lan Y; Deng X; Pan Y; Wang Y; Guan Y; Liu H; Chen F; Mo X; Tan X; Luo C; Wen X; Liu Y; Liu J; Zhang L; Tang X; Hu F; Li F
J Med Virol; 2021 Apr; 93(4):2505-2512. PubMed ID: 33433006
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
6. Elevation of Serum Carcinoembryonic Antigen Concentration Caused by Everolimus-Induced Lung Injury: A Case Report.
Komatsu H; Izumi N; Tsukioka T; Toda M; Hara K; Miyamoto H; Nishiyama N
Ann Thorac Cardiovasc Surg; 2018 Jun; 24(3):151-153. PubMed ID: 29249770
[TBL] [Abstract][Full Text] [Related]
7. Analytical and Clinical Performance of the Nanopia Krebs von den Lungen 6 Assay in Korean Patients With Interstitial Lung Diseases.
Cho EJ; Park KJ; Ko DH; Koo HJ; Lee SM; Song JW; Lee W; Lee HK; Do KH; Chun S; Min WK
Ann Lab Med; 2019 May; 39(3):245-251. PubMed ID: 30623616
[TBL] [Abstract][Full Text] [Related]
8. Serum Krebs von den Lungen-6 for Predicting the Severity of COVID-19 Lung Injury: A Systematic Review and Meta-Analysis.
Pramana Witarto A; Samarta Witarto B; Er Putra AJ; Pramudito SL; Rosyid AN
Iran Biomed J; 2021 Nov; 25(6):381-9. PubMed ID: 34641641
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Ishikawa N; Hattori N; Yokoyama A; Tanaka S; Nishino R; Yoshioka K; Ohshimo S; Fujitaka K; Ohnishi H; Hamada H; Arihiro K; Kohno N
Int J Cancer; 2008 Jun; 122(11):2612-20. PubMed ID: 18324627
[TBL] [Abstract][Full Text] [Related]
10. Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
Nakamura K; Kato M; Shukuya T; Mori K; Sekimoto Y; Ihara H; Kanemaru R; Ko R; Shibayama R; Tajima K; Koyama R; Shimada N; Nagashima O; Takahashi F; Sasaki S; Takahashi K
BMC Cancer; 2017 May; 17(1):302. PubMed ID: 28464801
[TBL] [Abstract][Full Text] [Related]
11. Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach.
Nishino M; Brais LK; Brooks NV; Hatabu H; Kulke MH; Ramaiya NH
Eur J Cancer; 2016 Jan; 53():163-70. PubMed ID: 26760924
[TBL] [Abstract][Full Text] [Related]
12. Plasma Krebs von den Lungen glycoprotein, lung injury, and noninvasive ventilation in Duchenne muscular dystrophy.
Hamada S; Ishikawa Y; Aoyagi T; Ishikawa Y; Minami R; Bach JR
Am J Phys Med Rehabil; 2012 Oct; 91(10):831-5. PubMed ID: 22760105
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.
Xue C; Wu N; Li X; Qiu M; Du X; Ye Q
BMC Pulm Med; 2017 Nov; 17(1):144. PubMed ID: 29149883
[TBL] [Abstract][Full Text] [Related]
14. Krebs von den Lungen 6 (KL-6) as a marker for disease severity and persistent radiological abnormalities following COVID-19 infection at 12 weeks.
Arnold DT; Donald C; Lyon M; Hamilton FW; Morley AJ; Attwood M; Dipper A; Barratt SL
PLoS One; 2021; 16(4):e0249607. PubMed ID: 33914762
[TBL] [Abstract][Full Text] [Related]
15. Clinical Usefulness of Serum Krebs von den Lungen-6 for Detecting Chronic Aspiration in Children with Severe Motor and Intellectual Disabilities.
Wakamoto H; Sano N; Yano Y; Sakai S; Kikuchi T; Fukuda M; Morimoto T; Ishii E
J Pediatr; 2015 Nov; 167(5):1136-42. PubMed ID: 26382626
[TBL] [Abstract][Full Text] [Related]
16. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.
Kuwana M; Shirai Y; Takeuchi T
J Rheumatol; 2016 Oct; 43(10):1825-1831. PubMed ID: 27481907
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics classified by the serum KL-6 level in patients with organizing pneumonia.
Yamaguchi K; Tsushima K; Kurita N; Fujiwara A; Soeda S; Yamaguchi A; Sugiyama S; Togashi Y; Kono Y; Kasagi S; Setoguchi Y
Sarcoidosis Vasc Diffuse Lung Dis; 2013 Mar; 30(1):43-51. PubMed ID: 24003534
[TBL] [Abstract][Full Text] [Related]
18. Treatment with everolimus for a patient with systemic metastatic breast cancer results in severe pulmonary injury: a case report.
Xiangying M; Tao W; Shikai W; Santai S; Zefei J
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):270-274. PubMed ID: 26932304
[TBL] [Abstract][Full Text] [Related]
19. SP-D, KL-6, and HTI-56 levels in children with mycoplasma pneumoniae pneumonia.
Shu LH; Lu Q; Han LY; Dong GH
Int J Clin Exp Pathol; 2015; 8(9):11185-91. PubMed ID: 26617840
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation.
Lesche D; Sigurdardottir V; Setoud R; Englberger L; Fiedler GM; Largiadèr CR; Mohacsi P; Sistonen J
Clin Transplant; 2015 Dec; 29(12):1213-20. PubMed ID: 26458301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
